Relationship betweenJAK2V617Fmutation, allele burden and coagulation function in Ph-negative myeloproliferative neoplasms

Prognostic significance of ASXL1, JAK2V617F mutations and JAK2V617F allele burden in Philadelphia-negative myeloproliferative neoplasms

BACKGROUND Despite insights into the genetic basis of Philadelphia-negative myeloproliferative neoplasms (Ph-negative MPNs), a significant proportion of essential thrombocythemia (ET) and primary myelofibrosis (PMF) patients present with no known MPN disease alleles. There were no previous studies investigating the impact of ASXL1 mutations in Ph-negative MPNs in Turkey. In the current study, w...

Prognostic significance of ASXL1, JAK2V617F mutations and JAK2V617F allele burden in Philadelphia-negative myeloproliferative neoplasms

License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be f...

jak2v617f allele burden measurement in peripheral blood of iranian patients with myeloproliferative neoplasms and effect of hydroxyurea on jak2v617f allele burden

background: myeloproliferative neoplasms (mpns) are clonal malignant diseases that represent a group of conditions including polycythemia vera (pv), essential thrombocythemia (et) and primary myelofibrosis (pmf). the aim of this study was to evaluate possible correlations between jak2v617f allele burden and clinicohematologic characteristics in iranian patients with mpns. we also aimed at deter...

Effects of Mutational Combinations on Philadelphia-Negative Myeloproliferative Neoplasms

The Ph-positive and Ph-negative myeloproliferative neoplasms: some topical pre-clinical and clinical issues.

This review focuses on topical issues in the biology and treatment of the myeloproliferative neoplasms (MPNs). Studies in transgenic mice suggest that BCR-ABL1 reduces the fraction of self-renewing 'leukemic' stem cells in the bone marrow but that some of these cells survive treatment with imatinib. This also seems to operate in humans. Data from models also strongly support the notion that JAK...